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Abstract 
A new approach to the modular, complex systems analysis of nonlinear dynamics 
in cell cycling network transformations involved in carcinogenesis is proposed. 
Carcinogenesis is a complex process that involves dynamically inter-connected 
biomolecules in the intercellular, membrane, cytosolic, nuclear and nucleolar 
compartments that form numerous inter-related pathways referred to as networks. One 
such family of pathways contains the cell cyclins.  Cyclins are proteins that link several 
critical pro-apoptotic and other cell cycling/division components, including the tumor 
suppressor gene TP53 and its product, the Thomsen-Friedenreich antigen (T antigen), 
Rb, mdm2, c-Myc, p21, p27, Bax, Bad and Bcl-2, which all play major roles in 
carcinogenesis of many cancers.  This novel theoretical analysis based on recently 
published studies of cyclin signaling, with special emphasis placed on the roles of cyclins 
D1 and E, suggests novel clinical trials and rational therapies of cancer through re-
establishment of cell cycling inhibition in metastatic cancer cells.   
 
Cyclins 
Cyclins are proteins that are often overexpressed in cancerous cells (Dobashi et al., 2004).   
Cyclin-dependent kinases (CDK), their respective cyclins, and inhibitors of CDKs (CKIs) were 
identified as instrumental components of the cell cycle-regulating machinery.  In mammalian cells 
the complexes of cyclins D1, D2, D3, A and E with CDKs are considered motors that drive cells to 
enter and pass through the “S” phase.  Cell cycle regulation is a critical mechanism governing cell 
division and proliferation, and is finely regulated by the interaction of cyclins with CDKs and 
CKIs, among other molecules (Morgan et al., 1995).   
 
 
The Genetic database I (DSI, Paris, France) Sequence for Cyclin-D1 is found at the PDB website:  
http://www.dsi.univ-paris5.fr/genatlas/fiche.php?symbol=CCND1 
 
 
A positive correlation has been noticed between overexpression of several cell-cycle proteins and 
unfavorable prognoses and outcomes in several different cancer types (van Diest et al., 1995; 
Handa et al., 1999; Fukuse et al., 2000).  In human lung tumors and soft tissue sarcomas, it has 
recently been discovered that cyclin A/cdk2 complex expression and kinase activity were reliable 
predictors of proliferation and unfavorable prognosis, thereby further substantiating the 
epidemiological factors of cyclin signaling (Dobashi et al., 2003; Noguchi et al., 2000). The 
Cdk2/Cyclin A forms a Complex with an 11-residue recruitment peptide from the Retinoblastoma-
Associated protein whose complex structure has been determined by X-ray Diffraction. 
 
 
p21 and p27 
 
The proteins p21 and p27 are also implicated in cyclin regulation and cancer development 
(Fig.1).  Mouse embryonic fibroblasts that were deficient for p21 and p27 were found to contain 
less cyclin D1 and D2 (Cheng et al., 1999) as well as cyclin D3 (Bagui et al., 2000) than controls.  
Similarly, mammary glands of p27-deficient mice were shown to possess decreased cyclin D1 
levels (Muraoka et al., 2001).  It has been demonstrated in vivo that p27 is necessary for 
maintaining proper levels of cyclins D2 and D3, and this dependency on p27 is common to a wide 
variety of cells/tissues in vivo.  The reduction of cyclin D levels under p27-deficient conditions 
equals the portion of cyclin D pool normally associated with p27 (Bryja et al., 2004).  The absence 
of p27 causes Leydig cells to produce double the testosterone, compared to controls (Bryja et al., 
2004), and p27 in Leydig cells appears to serve some other purpose besides regulating the G1/S 
transition (Bryja et al., 2004).  Regarding the molecular interaction between p27 and D-cyclin, 
CDK4 is a clear candidate as a mediating molecule (Bryja et al., 2004).   
       
 
The Dual Role of D-type Cyclins and p27 in Proliferation  
and Differentiation   
 
Cells employ CDK4/6– cyclin D complexes to flexibly titrate p27 from the complexes containing 
CDK2, and thereby they control their proliferation.  However, mutual dependency between cyclin 
D and p27 serves also some yet unidentified function in differentiation-related processes.  Thus, 
loss of p27 not only causes unrestricted growth due to inefficient inhibition of CDK2–cyclin E/A, 
but may also elicit a decrease in levels of D-type cyclins, resulting in differentiation defects.  Upon 
ablation of cyclin D, cells lose their ability to titrate p27 from CDK2–cyclin A/E complexes and 
proliferation is suppressed.  However, defects in differentiation caused by the absence of D-cyclin 
are reminiscent to defects produced by the absence of p27 (Bryja et al., 2004).  When the changes 
in levels of p27 and/or D-type cyclins occur, an equilibrium alteration could result between 
proliferation/differentiation processes that may in the end result in tumorigenesis (Bryja et 
al., 2004). 
 
D1 vs. E Cyclins 
 
The D-type and E-type cyclins control the G1  S phase transition during normal cell 
cycling and are important components of steroid- and growth factor-induced mitogenesis in breast 
epithelial cells (Sutherland and Musgrove, 2004).  Cyclin D1 null mice are resistant to breast 
cancer that is induced by the neu and ras oncogenes, which suggests a pivotal role for cyclin D1 in 
the development of some mammary carcinomas (Sutherland and Musgrove, 2004).  Cyclin D1 and 
E1 are usually overexpressed in breast cancer, with some association with adverse outcomes, 
which is likely due in part to their ability to confer resistance to endocrine therapies.  The 
consequences of cyclin E overexpression in breast cancer are related to cyclin E’s role in cell cycle 
progression, and that of cyclin D1 may also be a consequence of a role in transcriptional regulation 
(Sutherland and Musgrove, 2004).  One critical pathway determining cell cycle transition rates of 
G1  S phase is the cyclin/cyclin-dependent kinase (Cdk)/ p16Ink4A/ retinoblastoma protein 
(pRb) pathway (Sutherland and Musgrove, 2004).  Alterations of different components of this 
particular pathway are very ubiquitous in human cancer (Malumbres and Barbacid, 2001).   
 There appears to be a certain degree of tissue specificity in the genetic abnormalities within 
the Rb pathway.  A model relating Rb to cyclin control in the overall scheme of pro-apoptotic 
behavior is shown below in Fig.1.  In breast cancer these abnormalities include the overexpression 
of cyclins D1, D3 and E1, the decreased expression of the p27Kip1 CKI and p16Ink4A gene 
silencing through promoter methylation.  These aberrations occur with high frequency in breast 
cancer, as each abnormality occurs in ~40% of primary tumors.  This fact implicates a major role 
for the loss of function of the Rb pathway in breast cancer.  Cyclin D1 is the product of the 
CCND1 gene and was first connected to breast cancer after localization of the gene to chromosome 
11q13, a region commonly amplified in several human carcinomas, including ~15% of breast 
cancers (Ormandy et al., 2003).  The fact that cyclin D1 was overexpressed at the mRNA and 
protein levels in 50% of primary breast cancers have caused cyclin D1 to be considered one of the 
most commonly overexpressed breast cancer oncogenes (Gillett et al., 1994; Alle et al., 1998).   
 
Fig. 1.  Cancer Cell Cycling Model (substantially modified from Aguda, 2003). 
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Although cyclin E1 locus amplification is rare in breast cancer, the protein product is 
overexpressed in over 40% of breast carcinomas (Loden et al., 2002).  Cyclin D1 is predominantly 
overexpressed in ERC tumors, and cyclin E overexpression is confined to ER¡ tumors (Gillett et al., 
1994; Alle et al., 1998; Loden et al., 2002). 
The overexpression of several cell cycle regulators has been strongly associated with 
apoptotic-like behavior, as well as frank apoptosis, in cancer cells, which include c-Myc, E2F-1 
and HPV.  Apoptosis and its connection to cell cycle-related proteins is of interest therapeutically, 
as these types therapies could ultimately lead to the cancer cell annihilation via apoptosis.  
Recently, a shift has occurred, changing the focus of chemotherapy from exploration of agents that 
cause cell growth arrest to those that favor apoptosis. 
 
FGFR Tyrosine Kinases 
 
Fibroblast growth factor receptor (FGFR) tyrosine kinases have recently been studied as 
they relate to intracellular signaling and their effects on pRb, and are of interest to the field of 
cancer biology.  Overexpression of FGFR tyrosine kinases has been found in many human breast 
carcinomas and has been associated with poor clinical prognosis (Koziczak et al., 2004).  
Fibroblast growth factor receptors (FGFRs) are glycoproteins composed of extracellular 
immunoglobulin (Ig)- like domains, a hydrophobic transmembrane region and a cytoplasmic 
moiety that contains a tyrosine kinase domain (Koziczak et al., 2004).  When active, FGFRs 
stimulate tyrosine phosphorylation, as well as activation of several signaling molecules: Shc, PI3K, 
Src, PLCg, Crk, SH2 domain containing phosphatase-2 (SHP-2), p38, STAT1/3 and FGFR 
substrate 2 (FRS2) (Klint and Claesson-Welsh, 1999).  Treatment of tumor cells with the FGFR 
tyrosine kinase inhibitor leads to a reduction in pRb phosphorylation on serine 795, a site known to 
be phosphorylated by the cyclin D/cdk4 complex (Koziczak et al., 2004).  FGFR signaling may in 
fact promote cell proliferation by upregulating cyclin D levels.  This idea is supported by the fact 
that ectopic cyclin D1 expression is able to rescue the FGFR inhibitor-mediated antiproliferative 
effect (Koziczak et al., 2004).  Using a cyclin D1 reporter gene, Koziczak et al. (2002) found that 
FGFR inhibitor caused a significant reduction in promoter activity, and was reflected in an overall 
decrease in cyclin D1 mRNA levels.  
 
A recent study employed p27-deficient mice to investigate the significance of p27 for the 
metabolism of D-type cyclins in differentiated cells (Bryja et al., 2004).  The absence of p27 
resulted in decreased cyclins D2 and/or D3 levels in several organs. The drop in cyclin D levels 
that was due to the absence of p27 equaled the amount of cyclin D physically associated with p27 
animal controls.   
 
 
The Regulation Pathways of p27 Phosphorylation during Cell Cycling can be viewed at the 
NCI supported CGAP website:  
 
http://cgap.nci.nih.gov/Pathways/BioCarta/h_p27Pathway). 
 
This indicates the possibility that it is the proportion of p27-associated cyclin D that determines the 
response to p27 deficiency.  Cells in which the D-type cyclin level is dependent on p27 do not up-
regulate their CDK2 and CDK4 activities upon deactivation of p27.  Moreover, these cells have a 
negligible amount of p27 bound to CDK2 and/or cyclin A/E under non-cancerous conditions 
(Bryja et al., 2004).  These findings point to the existence of two roles for p27:  regulation of the 
cell cycle through inhibition of CDKs, and participation in the establishment or maintenance of the 
differentiated status that is achieved in conjunction with D-cyclins (Bryja et al., 2004).    
 
 Ubiquitin 
 
The regulation of protein stability via the ubiquitin–proteasome pathway is critical to the 
comprehension of the biomolecular basis of cancer development.  However, ubiquitin modification 
of substrates signals many cellular processes (besides proteolysis) that are also important for 
cancer development.  Interestingly, many breast cancer proteins studied by clinical researchers are 
involved in these specific ubiquitin pathways.  These proteins include cyclins, CDK inhibitors and 
the SCF in cell cycle control, the breast and ovarian cancer suppressor BRCA1-BARD1, 
ErbB2/HER2/Neu and its ubiquitin ligase c-Cbl, as well as and the estrogen receptor and its target, 
Efp.   
One function of the ubiquitin–proteasome proteolysis pathway is to label proteins for rapid 
degradation.  It consists of four enzymes: a ubiquitin-activating enzyme (E1), a ubiquitin-
conjugating enzyme (E2), a ubiquitin ligase (E3) and the 26S proteasome (Hershko and 
Ciechanover, 1998).  E1 binds to and activates ubiquitin in an ATP-dependent manner through a 
thiolester bond and then transfers ubiquitin to an E2 enzyme.  E2 then transfers ubiquitin to a 
lysine residue in the substrate via a terminal isopeptide bond through E3.  E3 is a scaffold protein 
that bridges in the substrate and the ubiquitin-bound E2.  The resultant covalent bonds of the 
ubiquitin ligations form polyubiquitinated conjugates that are quickly found and digested by the 
26S proteasome.  Understanding these pathways may provide many critical clues toward the 
development of novel diagnostic tools and treatments for cancer patients (Ohta and Fukuda, 2004). 
 
BRCA1-BARD1 Ubiquitin Ligase 
 
The breast and ovarian cancer susceptibility gene BRCA1 is probably the most studied 
gene in the breast cancer field because of its clinical significance and multiple functions.  The 
BRCA1 gene encodes a 1863-amino-acid protein (Miki et al., 1994) that consists of a RING-finger 
domain in its terminal N-region, a region that includes a nuclear localization signal and a domain 
that binds to many cellular proteins, and tandem BRCT domains in its C-terminal region. BRCA1 
is associated with a diverse range of biological processes, such as DNA repair, cell cycle control, 
transcriptional regulation, apoptosis and centrosome duplication.  The only known biochemical 
function of BRCA1 is E3 ubiquitin ligase activity (Table 1).  The N-terminal RING finger domain 
of BRCA1 interacts with another conformationally similar RING finger protein, BARD1 (Wu et 
al., 1996; Brzovic et al., 2001), that also contains an N-terminal RING domain and C-terminal 
BRCT domains (Wu et al., 1996).  BRCA1 attains high ubiquitin ligase activity when bound to 
BARD1 as a heterodimer (Hashizume et al., 2001).  Importantly missense mutations in the RING-
finger domain of BRCA1 found in familial breast cancer all eradicate the ubiquitin ligase activity 
of BRCA1-BARD1 (Hashizume et al., 2001; Ruffner et al., 2001; Brzovic et al., 2003). This fact 
suggests a strong link between BRCA1 ligase activity and its function as a tumor suppressor.  The 
analysis of ubiquitin ligase activity of RING-domain mutations is important not only for the 
investigation of the biological function of BRCA1, but also to be able to predict a specific patient’s 
propensity for cancer, which may influence the need for prophylactic surgeries. 
 
Ubiquitin E3 ligases and their targets related to breast cancer 
 
Besides enhancing BRCA1’s ubiquitin ligase activity, BARD1 is also critical for BRCA1 
stability in vivo (Hashizume et al., 2001; Joukov et al., 2001; Xia et al., 2003).  Loss of BARD1 
leads to a phenotype similar to that of the loss of BRCA1, that is, early embryonic lethality/ 
chromosomal instability (McCarthy et al., 2003).  Moreover, germline mutations of BARD1 are 
found in breast and ovarian cancer patients (Thai et al., 1998).  Although ubiquitin ligase activity 
may be significant for the role of the BRCA1 gene as a tumor suppressor, the way the activity 
contributes to BRCA1’s biological function remains unknown.  Two issues exist that are critical to 
the elucidation of the role of the BRCA1-BARD1 ubiquitin ligase: the type of polyubiquitin chain 
built by BRCA1-BARD1 (and its consequences), and the specific identity of its substrates. 
 
In the past decade researchers have identified important functional roles for the D- and E-
type cyclins in the evolution of human breast cancers.  These genes are among the most commonly 
overexpressed genes in breast cancer, being overexpressed in the early phases of disease and 
having proven oncogenic effects on mammary epithelial cells both in vitro as well as in vivo.  
Their established role in CDK activation and Rb pathway regulation has directed scientific 
attention toward aberrant cell cycling as the basis of oncogenic potential.  More recent data on the 
role of different G1 cyclins in the areas of differentiation, chromosome stability and transcriptional 
regulation indicate that their role in breast cancer is much more complex than initially predicted.   
Further investigations may yield a more complete understanding of the role of these cyclins 
regarding the biomolecular basis and pathophysiology of breast cancer, with significant potential 
benefits clinically, through the identification of novel markers of prognosis and therapeutic 
responsiveness and potential new targets for innovative clinical intervention. 
 
Signal Transduction Modulators as Novel Anticancer Drugs 
 
Recently, there has been an increasing number of reports that cancer frequently involves 
pathogenic mechanisms which give rise to numerous alterations in signal transduction pathways. 
Therefore, novel therapeutic agents that target specific signal transduction molecules or signaling 
pathways altered in cancer are currently undergoing clinical trials often with remarkable results in 
cancer treatments of patients in which chemo- and/or radio- therapy resistant tumors have become 
established.  For example, a new class of anticancer drugs, the (protein) tyrosine/ threonine kinase 
inhibitors, such as: STI-571 (‘Gleevec’, or Imatinib Mesylate), ZD-1839 (‘Iressa’), OSI-774, and 
flavopiridol, are ATP-site antagonists and have recently completed phase I and phase II trials. Also 
directed against signal transduction targets are the monoclonal antibodies Herceptin and C225.  
Several other kinase antagonists are currently undergoing clinical evaluations, including UCN-01 
and PD184352.  Other strategies for downmodulating kinase-driven signaling include 17-allyl-
amino-17 demethoxygeldanamycin and rapamycin derivatives. Phospholipase-directed signaling 
may also be modulated by alkylphospholipids.  Farnesyltransferase inhibitors, originally developed 
as inhibitors of ras-driven signals, may attain activity by affecting other or additional targets.  
Signal transduction is an efficient method for fine-tuning the development and modeling of cancer 
treatments. The following detailed background on clinical trial and signal transduction modulators 
as novel anticancer drugs summarizes the contents of a recent NCI Report (Sausville, Elsayed, 
Monga and Kim, 2003) and references cited therein. 
 
Tyrosine Kinase Inhibitors 
 
STI-571 (‘Gleevec’ or Imatinib Mesylate) inhibits three kinases:  Abl (all forms), PDGFR 
and c-kit tyrosine kinases.  It blocks the Bcr-Abl tyrosine kinase, and is important in chronic 
myelogenous leukemia (CML) patients because CML cells have constitutively active Bcr-Abl 
tyrosine kinase.  STI-571 differentially inhibited the growth of p210Bcr-Abl CML and p185Bcr-Abl 
CML containing acute lymphoblastic leukemia cells and does not affect the normal marrow cells.  
The effect of STI-571 is exciting because it inhibits c-kit/CD117 positive tumors owing to the 
paucity of interventions for these chemoresistant tumors. For example, significant response in 
rapidly progressive gastrointestinal tumors (GIST) and soft-tissue sarcomas that were previously 
resistant to cytostatic, anticancer drugs when Gleevec is not administered simultaneously with such 
cytostatics.  FDA has approved Gleevec for GIST as well as CML treatments, and is undergoing 
clinical trials for novel therapeutic strategies of other types of cancer. 
 
SU5416 is a ATP-site antagonist of the vascular endothelial growth factor (VEGF) 
(Flk1/KDR) receptor was designed following studies of the indolin-2-one pharmacophore and the 
fibroblast growth factor (FGF) receptor tyrosine kinase domain. A Lineweaver-Burk analysis 
showed SU5416 to be a competitive inhibitor with ATP for the Flk1/KDR and PDGF receptors (Ki 
0.16 µM and 0.32 µM, respectively) (Mohammadi et al., 1997; Mendel et al., 2000).  The first 
SU5416 clinical trial enrolled 63 patients and administered the drug i.v. biweekly (Rosen et al., 
1999);  at the higher doses, nausea, vomiting, headache and some liver toxicity were 
noticed;[ stable disease of greater than 6 months duration was the only reportable outcome in 
patients with a variety of advanced diseases (colorectal, lung, renal and Kaposi's sarcoma.  Patients 
with significant progression suffered noticeable increases in vascularity; the occurrence of vascular 
complications like thrombotic events raises the risk of broad application of this drug (Kuenen et al., 
2002). 
 
Tyrosine Kinase/EGFR Inhibitors 
 
ZD 1839 (‘Iressa’).  Epidermal Growth Factor Receptor (EGFR) activates several 
downstream signaling pathways and is overexpressed in numerous types of human cancers, 
including: non-small cell lung (NSCLC), colorectal, head and neck, bladder, brain, pancreas, 
breast, ovary, prostate, and gastric cancers (Salomon et al., 1995; Gullick et al., 1991). 
Overexpression of EGFR is associated with increased invasiveness, resistance to treatment and 
poor outcomes in several tumor types (Neal et al., 1985; Ke et al., 1998).  Iressa is found to be 
effective in the treatment of: Non-small cell lung (NSCLC), colorectal, head and neck, bladder, 
brain, pancreas, breast, ovarian, prostate and gastric cancer types that were previously 
unresponsive to other chemotherapy (Salomon et al., 1995; Gullick et al., 1991).  ZD 1839 (Iressa) 
blocks EGFR; ZD1839 inhibits autophosphorylation, and results in complete regression in some 
xenograft tumors (Ciardiello et al., 2000; Sirotnak et al., 2000) when used with cytotoxic drugs 
such as doxorubicin, or in combination with radiation.  Iressa inhibits the Ras/MAP kinase and 
STAT-3 transcription factors, in many tumors; the inhibition of the epidermal growth factor 
receptor (EGFR) has been of significant interest lately, partially because of the autocrine activation 
of EGFR and several downstream pathways, such as the ras/MAP kinase and STAT-3 transcription 
factors, in several tumors. The activated EGFR pathway induces entry into the cell cycle, inhibition 
of apoptosis, and also activation of angiogenesis and motility. Several phase I and II studies with 
Iressa have already been completed (Ferry et al., 2000; Negoro et al., 2001; Baselga et al., 2000). 
Daily oral doses have ranged from 50 to 700 mg for 2 to 4 weeks.  ZD1839 resulted in some 
responses in NSCLC and prostate cancer, and stability of disease (over 4 months) in several 
patients (Ferry et al., 2000; Negoro et al., 2001; Baselga et al., 2000).  22% of Japanese patients 
achieved partial response (Negoro et al., 2001). Side effects have been relatively mild and have 
included diarrhea and rash. 
 
OSI-774, Erlotinib, or ‘Tarceva’ is also an EGFR inhibitor; it binds very tightly to EGFR, 
causing EGFR inhibition.  It produces downstream inhibition of the P13/MAPK signal 
transduction pathways, resulting in accumulation of p27, that leads to cell cycle arrest at the 
G1 phase and induction of apoptosis (Moyer et al., 1997).  EGFR-TK is more than 1000 fold 
sensitive to ‘Tarceva’ compared with any other tyrosine kinases.  Therefore, it is a very specific 
inhibitor of EGFR –TK and reduces very markedly the phosphorylated EGFR-TK.  The IC50 
for Tarceva is 2 nM (when measured by purified EGFR-TK inhibition in biochemical assays), and 
its value is 20 nM for the EGFR-TK autophosphorylation when measured in intact cells.  The 
proposed mechanism of action: reversible inhibition of EGFR-TK through competitive binding to 
the ATP site.  Results of preliminary Clinical Trials include: partial responses in patients with 
colorectal cancer and renal cell carcinoma (kidney), as well as > 5 month stabilization in: colon, 
prostate, cervical, NSCLC and head and neck cancers.   
 
Herceptin (Trastuzumab), a recombinant humanized monoclonal antibody directed against 
HER2 is known as ‘Herceptin’ (Carter et al., 1992).  The HER2/neu gene increases the kinase 
activity, initiating signal transduction, leading to proliferation and differentiation in approximately 
30% of human breast cancers (up to 50 to 100 gene copies/cell).  The HER2/neu gene makes a 
type I receptor tyrosine kinase encoding a 185 kDa surface membrane receptor protein.  Phase I 
trials showed that the dose of trastuzumab (i.v. 10 to 500 mg single dose or weekly) could be 
increased without toxicity and that pharmacokinetics were dose-dependent (Shak et al., 1999).  
Phase II trials response is > 5.3 months.  Phase III trial patients received doxorubicin or epirubicin 
plus cyclophosphamide, and 28% of patients treated with chemotherapy and trastuzumab were free 
of tumor progression, compared with 9% of the patients treated with chemotherapy alone.  The 
monoclonal antibody of the membrane receptor HER2 signaling protein is much more efficient 
than chemotherapy alone.  About 1 in 5 of the patients had cardiac dysfunction, where trastuzumab 
was at 4 mg/kg body weight initially.  A phase II trial was conducted with 46 HER2 (+) metastatic 
breast cancer patients who had failed prior cytotoxic chemotherapy (Baselga et al., 1996).  
Objective responses were seen in 5 of 43 assessable patients, including 1 complete remission and 4 
partial remissions.  A second phase II trial (Pegram et al., 1998) combined trastuzumab with 
cisplatin in 39 HER2 (+) metastatic patients who had failed prior chemotherapy.  Of the 37 
subjects, 9 achieved a partial response and 9 had a minor response or stability.  A randomized, 
placebo-controlled phase III study was performed to determine efficacy and safety of adding 
trastuzumab to chemotherapy in breast carcinoma.  28% of patients treated with both were disease 
progression-free at 12 months, compared with 9% of the patients treated only with chemotherapy.  
The treatment is indicated as a single agent for patients that have failed earlier therapy, and it is 
used also as first-line treatment for metastatic disease when used in combination with paclitaxel.  
Trustuzumab has been approved by the FDA for use in women with metastatic breast cancer with 
HER2-positive tumors. 
 
Cetuximab.  An antibody-based approach to affecting tyrosine kinase signaling is by 
cetuximab, a humanized monoclonal antibody against the EGFR.  MAb225, a murine monoclonal 
antibody that specifically binds to EGFR, specifically competes with signal transduction initiated 
by TGF- (Gill et al., 1984). Cetuximab (C225) is the human-mouse chimeric version of Mab225, 
which specifically binds to the EGFR with high affinity, preventing the ligand from interacting 
with the receptor.  Preclinical studies show that cetuximab results in cell-cycle arrest as well as 
apoptosis in different contexts (Huang et al., 1999; Peng et al., 1996). A synergistic effect of 
cetuximab with cytotoxic chemotherapy has been seen with cisplatin, doxorubicin (Baselga et al., 
1993), gemcitabine (Bruns et al., 2000), docetaxel (Tortora et al., 1999), and paclitaxel (Inoue et 
al., 2000).  Early phase I trials demonstrated that cetuximab displays nonlinear, dose-dependent 
pharmacokinetics that are not altered by coadministration of cisplatin (Baselga et al., 2000).  These 
studies were conducted in patients with tumors overexpressing EGFR.  There were only 5 episodes 
of severe C225-related toxicities among the 52 patients.  Two patients with head and neck tumors 
who received cetuximab at doses of 200 mg/m2 and 400 mg/m2 with cisplatin exhibited a partial 
response. In light of these results, the clinical development of cetuximab is continuing with a 
number of phase II and III studies. 
 
Serine-Threonine Kinase Antagonists (STKAs) 
 
Rapamycin Congeners.  Rapamycin (Sirolimus, Rapamune) is a macrolide fungicide that 
binds intracellularly to the immunophilin FKBP12, and the resultant complex inhibits the activity 
of a 290-kDa kinase known as mammalian target of rapamycin (mTOR). Rapamycin is isolated 
from the bacteria Streptomyces hygroscopicus and is found to have potent antimicrobial and 
immunosuppressive properties (Baker et al., 1978).  Sirolimus was approved by the FDA for 
prevention of allograft rejection after organ transplantation (Sehgal et al., 1995).  Further studies 
with rapamycin revealed significant antitumor activity (Eng et al., 1984). This is understandable 
given the importance of mTOR in mitogenic cell signaling. mTOR is a kinase member of PI3K-
related kinase family that is activated in response to growth signaling through the PI3K/Akt 
pathway. Activation of mTOR results in increased translation of several critical cell-cycle 
regulatory mRNAs through two downstream effector kinases, p70S6K and 4E-BP1/PHAS (Sekulic 
et al., 2000; Gingras et al., 1998). Rapamycin causes G1 cell-cycle arrest by increasing the turnover 
of cyclin D1 (Hashemolhosseini et al., 1998), preventing upregulation of cyclins D3 and E (Decker 
et al., 2001), upregulating p27KIP1, and inhibiting cyclin A-dependent kinase activity (Kawamata et 
al., 1998). Several analogs of rapamycin have been selected for further development as anticancer 
agents.  CCI-779, an ester of rapamycin, has significant antiproliferative effect and favorable 
toxicology profile and is being studied in several phase I trials in humans (Hidalgo et al., 2000; 
Raymond et al., 2000).  Several partial responses have been documented in renal cell carcinoma, 
NSCLC, neuroendocrine tumors, and breast cancer, in addition to minor responses or stable 
disease in several tumor types (Hidalgo et al., 2000; Raymond et al., 2000).  RAD001, an orally 
bioavailable hydroxyethyl ether derivative of rapamycin, also has potent activity against various 
animal xenograft models of human tumors; an antiangiogenic effect may account in part for its 
antiproliferative properties (O’Reilly et al., 2002). 
MEK Inhibitor, PD 184352.  The stimulation of Ras-mediated signal pathways results in 
a cascade of downstream kinase activation including Raf, which phosphorylates two distinct serine 
residues on the dual-specificity kinase MEK (MAP kinase-kinase) (Lewis et al., 1998).  MEK, in 
turn, activates and exclusively phosphorylates two subsequent kinases, ERK1 and ERK2 (MAPK), 
on specific tyrosine and threonine residues within each kinase. These kinases phosphorylate a 
variety of substrates including transcription factors critical to cell proliferation and tumor invasion 
(e.g., Marais et al., 1993).  In cytotoxicity studies, correlation between sensitivity to PD184352 and 
increased activated MAPK levels was observed in some cells in particular, colon cancer cells. 
Higher levels of MAPK activation were observed in colon tumor tissue versus normal mucosa as 
this event occurs late in colon carcinogenesis (Sebolt-Leopold et al., 1999).  In mice with colon 26 
xenograft model treated with PD184352, excision and assay of tumor cells revealed diminished 
phospho-MAPK levels. After drug withdrawal, a return to baseline levels was observed reflecting 
the cytostatic nature of the inhibition. The pharmacodynamic measurement of activated MAPK in 
tumor tissue may be used as a biological marker of drug activity as antibodies specific for 
phosphorylated MAPK are available. 
 
Bryostatin.  The bryostatins represent a large family of secondary metabolites produced in 
extremely small amounts by the marine invertebrate, Bugula neritina of the phylum Ectoprocta 
(Pettit et al., 1991). The various bryostatins are distinguished by varying side chains off the 
macrocyclic lactone ring structure. Despite this close structural relationship, these nontumor-
promoting PKC activators have different biologic activities and spectrum of toxicity (Kraft et al., 
1996; Jones et al., 1990). Bryostatin 1 (Bryo 1) is the prototype of this 17-member family and the 
most extensively studied in humans. Initial isolation of Bryo 1 was based on its antineoplastic 
activity against the murine P388 lymphocytic leukemia.  Bryo 1 is a potent and rapid activator of 
PKC; however, unlike other PKC activators, including phorbol myristate acetate (PMA), Bryo 1 
lacks tumor-promoting capabilities.  The first two published phase I trials evaluated Bryo 1 
administered as a 1 h intravenous infusion (Prendiville et al., 1993; Philip et al., 1993).  The DLT 
was myalgia, occurring approximately 48 h after treatment and lasting up to several weeks at the 
highest dose levels (65 g/m2/dose).  The MTD was 50 g/m2, and the recommended dose for 
phase II trials was 35 to 50 g/m2 every two weeks. Partial responses were observed in two 
patients with malignant melanoma, which lasted 6 months and 10 months.  Plasma levels of tumor 
necrosis factor-alpha (TNF-) and interleukin-6 (IL-6) increased 2 h and 24 h after treatment, 
respectively, and were dose related. 
 
UCN-01 (7-OH Staurosporine):  Staurosporine, a natural product isolated from 
Streptomyces staurosporeus, is a relatively broad, nonspecific protein kinase antagonist, originally 
isolated in an effort to define inhibitors of protein kinase C (PKC).  7-OH staurosporine (UCN-01) 
was defined as a more selective, but not specific, PKC antagonist.  Two prominent effects of UCN-
01 have emerged in preclinical studies in vitro: induction of cell-cycle arrest, and abrogation of the 
checkpoint to cell-cycle progression induced by DNA damaging agents. UCN-01 inhibited cell 
growth in several in vitro and in vivo human tumor preclinical models (Akinaga et al., 2000); 
however, antiproliferative activity on the part of UCN-01 cannot be explained solely by inhibition 
of PKC. First, in cell-cycle analyses UCN-01 inhibits Rb+ cells at G1/S phase of the cell cycle 
(Akiyama et al., 1997). In addition, cells treated with various concentrations of UCN-01 showed 
decreased pRb phosphorylation in a dose-dependent manner (Chen et al., 1999). These results 
suggest that CDK2- or CDK4-regulated steps are targets for UCN-01-induced cell-cycle arrest.  
UCN-01 abrogates the DNA damage-induced checkpoints to cell-cycle progression in G2 (Bunch 
et al., 1996; Wang et al., 1996) and in S phase (Shao et al., 1997). It is noteworthy that these 
effects were apparent at drug concentrations that appeared to have little direct effect on cell 
proliferation or that caused enhanced cytotoxicity by clonogenic or proliferation assays. In 
addition, they provided a mechanistic framework for prior observations that DNA-damaging 
agents such as mitomycin (Akinaga et al., 1993) could greatly potentiate UCN-01 action.  In 
contrast to animal studies, UCN-01 displayed strong binding to human plasma proteins, apparently 
to the 1-acid glycoprotein (AAG) in initial human phase I clinical trials (Sausville et al., 2001; 
Fuse et al., 1998).  One partial response occurred in a patient with melanoma, and a protracted (>4 
year) period of stabilization of minimal residual disease was observed in a patient with alk(+) 
anaplastic large cell lymphoma. 
 
Miltefosine and Perifosine (ALP Analogs).  Certain alkylphospholipids (ALP) (e.g., Rac-1-
O-octadecyl-2-O-methyl-glycero-3-phosphocholine [ET-18-OCH3, edelfosine]) when given to 
mice prior to transplantation of Ehrlich ascites carcinoma cells, effectively prevent growth of this 
tumor (Tarnowski et al., 1978). Enhancement of immune defense against tumor cells was initially 
considered a plausible mechanism and has been demonstrated on multiple occasions by a number 
of ALP analogs.  Edelfosine is also able to induce apoptosis in HL60 leukemic cells, even in low 
concentrations and after short incubation times. In U937 leukemic cells, the compound induced 
apoptosis rapidly, whereas in epithelial HeLa tumor cells this induction required prolonged times 
of treatment (Mollinedo et al., 1993).  All ALP analogs studied so far cause an indirect inhibition 
of PKC, most likely as a result of the reduced formation of diacylglycerol through inhibition of 
phospholipase C (Uberall et al., 1991; Seewald et al., 1990). Additional antiproliferative 
mechanisms could involve altered growth factor receptor function, as well as recent evidence of 
p21 induction by an as yet undefined pathway (Patel et al., 2002) irrespective of p53 function.  
Eight phase I-II studies, consisting of 443 patients using topically applied miltefosine 2%-8% for 
skin metastases in patients with breast cancer, showed a median response rate of 38% (Unger et al., 
1988; Smorenburg et al., 2000; Terwogt et al., 1999).  Evidence from the trials led to the approval 
of miltefosine, licensed as Miltex©, in Germany for the treatment of cutaneous breast cancer and 
cutaneous lymphomas.  The heterocyclic alkylphosphocholine derivative octadecyl-(1,1-dimethyl-
piperidino-4-yl) phosphate (D-21266; perifosine) was developed and selected for improved 
gastrointestinal tolerability. A number of phase I studies are presently ongoing in Europe and the 
United States; early evidence points to better tolerability and less gastrointestinal toxicity 
(Messmann et al., 2001). 
 
Proteosome Inhibitor PS-341.  The proteasome, a multicatalytic protease responsible for 
degradation of most proteins with the cell, has emerged as a new target for anticancer drug 
development. The 20S proteasome is involved in the degradation of several cell-cycle regulatory 
proteins such as cyclins (A, B, D, E), cyclin-dependent kinase inhibitors (p21WAF1/CIP1 and p27), 
oncogenes (c-fos/c-jun, c-myc, N-myc), and p53 and regulatory proteins (I B, p130) (King et al., 
1996).  Inhibition of the 20S proteasome pathway aims at altering the cell cycle to promote 
apoptosis (An et al., 2000). Although the proteasome is present in all cells, transformed and 
dividing cells are most sensitive to its inhibition (Drexler et al., 1997).  PS-341 is the first 
proteasome inhibitor to enter human trials. It is a boronic acid dipeptide that specifically inhibits 
the 20S proteasome presumably through the stability of a boron-threonine bond that forms at the 
active site of the proteasome. It was found to have substantial cytotoxicity against a wide range of 
human tumor cells in the NCI 60 cell line anticancer drug screen (Adams te al., 1999).  PS-341 
causes accumulation of cyclin A, cyclin B, p21WAF1/CIP1, and wild-type p53 and arrests the cells at 
the S and G2/M phases followed by nuclear fragmentation and apoptosis. PS-341 significantly 
inhibited NF- B DNA binding and functional reporter activity (Sunwoo et al., 2001).  Several 
phase I studies evaluated various schedules of PS-341 administration. At the MTD recommended 
for phase II studies (1.25 mg/m2-1.3 mg/m2), a 65%-72% inhibition of 20S proteasome was 
achieved (Erlichman et al., 2001; Aghajanian et al., 2001). An average 54% inhibition of 
proteasome was achieved in patients' tumors (Hamilton et al., 2001). In these phase I studies 
several patients achieved partial responses and disease stabilization including a bronchoalveolar 
NSCLC, melanoma, sarcoma, lung adenocarcinoma, and malignant fibrous histiocytoma. Patients 
usually had more toxicity with the second cycle of treatment. Currently several phase II clinical 
trials are evaluating PS-341 as a single agent in hematologic malignancies, neuroendocrine, renal 
cell, melanoma, breast, brain, pediatric tumors, and several other solid tumors. Significant 
antitumor effects were documented in a phase II study of PS-341 in refractory multiple myeloma 
(Richardson et al., 2001). 
 
 
Farnesyl Transferase Inhibitors 
 
 Ras genes are mutated in 30% of all human cancers with K-Ras being the most common. 
This family of genes encodes GTP binding proteins important in malignant transformation, cell 
growth, and intracellular signal transduction.  Normal ras binds GTP and in the GTP-bound state 
interacts with numerous effectors including the raf proto-oncogene kinase and phosphatidyl-
inositol 3-kinase.  Three isoforms, Harvey(Ha), Kirsten(K), and N-isoforms have been described, 
with mutation of the GTPase of the K isoform resulting in a persisting signaling capacity in 
approximately 20% of human epithelial tumors. N-ras is mutated in a smaller proportion of 
malignancies, predominantly leukemias. Ras function requires lipophilic anchorage to the cell 
membrane by lipid prenylation. This requires posttranslational modification or covalent thioether 
bond formation between a farnesyl group (C15) and a cysteine residue at the ras carboxy terminus.  
A "GTT shunt pathway" maintains K-Ras in an active prenylated, membrane-bound form and 
explains in part the requirements for higher farnesyl transferase inhibitor (FTI) dose or cotreatment 
with a GTT inhibitor for significant growth inhibition in K-Ras models (Pendergast et al., 2000). 
Several classes of FTIs have been developed in an initial effort to define inhibitors of Ras function 
and, in general, compete with the enzyme substrates, the CAAX tetrapeptide, and farnesyl 
pyrophosphate (FFP). The CAAX competitors are generally peptidomimetic agents that mimic the 
carboxy terminal portion of the Ras protein. 
 
 SCH66336 is a novel oral agent derived from a class of nonpeptide, nonthiol-containing, 
CAAX mimetic FTIs (Bishop et al., 1995).  The drug inhibits in vitro FT activity with an IC50 of 
1.9 nM for H-ras, 2.8 nM for N-ras, and 5.2 nM for K-ras. Inhibition of cells with activated ras and 
anchorage-independent growth was noted with IC50 75 nM in H-ras versus 400 nM with K-ras-
driven cells (Liu et al., 1999).  The observed growth inhibition of tumor cells in soft agar and in 
xenografts was independent of ras mutational status because even wild-type ras cells were 
sensitive (Liu et al., 1998).  The phase I experience with SCH66336 involved 20 patients using a 
twice a day schedule over 7 days every 21 days.  Eight patients had stable disease, and treatment 
for up to 10 cycles was possible in a few patients. Antitumor activity was reported in one patient 
with advanced NSCLC who had a greater than 50% reduction in an adrenal metastasis and 
received treatment for 14 months (Adjei et al., 2000). 
 
 R115777 is a substituted quinolone and competitive inhibitor of the CAAX peptide binding 
site of FT (End et al., 1999). The compound inhibits in vitro K-Ras farnesylation (IC50 7.9 nM) and 
exerts antiproliferative effects in cell lines such as H-Ras-transformed fibroblasts (IC50 1.7 nM) 
and K-Ras-driven colon and pancreatic cells lines (at roughly IC50 20 nM) (End et al., 2001).  The 
initial clinical experience with R115777 in 27 patients was reported by Zujewski et al. (Zujewski 
et al., 2000).  Of the 27 patients treated, 8 had stable disease after 3 treatment cycles, and 4 patients 
continued treatment with the longest reaching 5 months. A patient with metastatic colon cancer 
had symptomatic improvement and a 50% reduction in carcinoembryonic antigen (CEA) levels.  In 
another phase I study with R115777, two patients with stable disease exceeding 6 months were 
reported.  A partial response in a NSCLC patient lasting 4 months was reported (Schellens et al., 
2000).  Finally, 3 advanced breast cancer patients treated continuously at 300 mg twice a day 
attained confirmed partial responses whereas another 9 patients had stable disease of at least 3 
months duration (Johnston et al., 2000). 
 
 A very interesting outcome was obtained in patients with myelodysplastic syndrome or 
relapsed or poor prognosis leukemias, where a phase I dose escalation study revealed DLT at 1200 
mg twice per day, consisting of neurotoxicity, with non-DLTs including renal insufficiency and 
myelosuppression. There was clear evidence of downmodulation of erk kinase activity, along with 
the farnesylation status of lamin A and HDJ-2. Clinical responses occurred in 29% of 34 evaluable 
patients, including 2 complete responses (Karp et al., 2001). Though there were no mutations in N-
Ras detected in this patient population, this study did suggest that in addition to clinical activity 
there was some evidence of downmodulation of signaling as well as farnesylation-directed 
activities. 
 
Conclusions  
 
Specific Results on the use of Signal Transduction Modulators as Novel 
Anticancer Drugs 
 
1. Gleevec, Herceptin (Trastuzumab) and CCI-779 have been approved by FDA for 
treatments of several types of cancer.  
2. Preclinical studies with C225 showed that ‘Cetuximab’ results in cell cycle arrest, as well 
as apoptosis in several types of tumors, and it had synergistic effects with cytotoxic 
chemotherapy; Cetuximab (C225) was reported to be tested further in Phase II and III 
clinical trials.  
3. Flavopiridol : The goal would be to develop new STKAs that would be similar to 
flavopyridol, or HMR 1275. Some STKAs act as blockers of Cyclin D1, therefore causing 
cycle arrest by direct transcription repression of cyclin D1 mRNA (79), and in mantle cell 
lymphoma, flavopyridol delayed significantly progression of disease in 84% of patients 
(80).Cytostasis effects are significant and were observed with the flavopyridol to colorectal 
and prostate carcinoma xenograft models.  
 
Evaluation of Results and Related Developments 
The results obtained so far in clinical trials convey the promise as well as the challenges 
encountered in developing signal transduction inhibitors (STIs) for significant improvements of 
cancer treatment efficacy with such new anticancer drugs. These STI molecules represent a 
marked departure from prior chemotherapeutic approaches that have been, and still are, mostly 
based on cytotoxic anticancer drugs. The fact that encouraging responses with a number of novel 
STIs have been seen in cancer patients-- as expected from mechanistic in vitro experiments-- 
reaffirms the relevance of Integrated Cancer Biology research in charting the future course of 
cancer developmental therapeutics, and especially the importance of understanding signaling 
transduction functions and the underlying biodynamics in signaling pathways of cancer cells. On 
the other hand, the initial results obtained raise a number of issues that should be considered before 
the field can advance towards the eradication of cancer. One such major issue is the lower response 
observed clinically in cancer patients with some of the new STIs compared to the expected value. 
Whereas some anticancer agents have entered initial clinical trials with extensive efforts to 
document target-based effects in conjunction with pharmacology and clinical toxicity evaluations, 
other agents have not done so, and in those instances the phase I study has no depth, and does not 
provide valuable information.  Therefore, lacking clear evidence of definite clinical response, one 
cannot confidently move forward to the next trail phase.   
Effective, rational design of combinations with standard cytotoxic agents also remains a 
challenge in the absence of basic information on anticancer drug interactions.  Preclinical models 
of synergistic effects with signaling agents often proceeds from empiricism rather than 
understanding on a mechanistic basis, which is what should guide clinical implementation. 
Another important aspect that must be considered is the need for accurate means of diagnosing the 
dependence of a tumor on a particular signaling pathway, or target, for novel therapeutic strategies. 
All of problems and drawbacks considered here call for renewed efforts to define improved assays 
of target effects in the preclinical phase of a drug's development that can also be translated to the 
clinical arena. Microarray, proteomic and interactomic, approaches offer the promise of providing 
such means (Mohr, S. et al., 2002) but these must also be integrated into the clinical trials process.  
The vast amounts of data becoming available from such high throughput measurements 
with microarrays on human tumors and tissues also require the employment of powerful computers, 
effective algorithms for data computational analysis, as well as major advances in our 
understanding of the complex systems dynamics of cancer cells, malignant tumors and tumor-
immune interactions in human subjects. Furthermore, higher sensitivity, faster and less expensive 
diagnostic means must be developed and tested in the clinic to establish their applicability to 
different types of cancer, and also for the early detection of cancer. Molecular profiling and 
selective molecular imaging of cancer in human subjects are two such closely related diagnostic 
means that would make possible individualized cancer therapy, as well as provide the ability to 
proceed with economically feasible screening of human populations that are considered to be at 
risk for specific types of cancer by utilizing relatively inexpensive and non-invasive means for 
early detection of cancer. NIR and fluorescence microspectroscopy based techniques are two such 
very promising means for the early detection of cancer, as well as for the effective monitoring of 
the cancer therapy effects in patients, thus also providing the accurate means for diagnosing the 
dependence of a tumor on a particular signaling pathway, or target, for novel therapeutic strategies. 
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